With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were completed in less than six weeks, from approach to announcement, according to Lazard’s data. Michael Kingston …

Send us a text In this episode of Decoding Health, we dive deep into the world of pharmaceutical drug manufacturers, focusing on Catalent and their financial strategies. We explore how funding and spending decisions shape the availability and marketing of critical drugs, including a discussion on the patents governing popular medications like Ozemp…

Dexter Yan回顾了他在国庆长假前和阿斯利康全球执行副总裁-生物制药研发负责人Sharon Barr的采访。此外，本期播客迎来了Citeline Insights团队在上海的新成员、资深记者Xu Hu。她分享了先为达生物伊诺格鲁肽的最新III期临床数据，以及中国律师对美国生物安全法案影响的分析。Av Citeline

In this month’s episode of Evaluating Biopharma, host Ben Locwin and Chris Major, founder and partner of BioProcess360 Partners, discuss the best ways to start a company to address technology gaps, why it is beneficial to collaborate with competitors (instead of going against each other), and the challenges encountered when planning to de-risk port…

In this insightful episode of Driving Digital in Biopharma, host Tom Lehmann explores with Áine Hanly, Chief Technology Officer at Vir Biotechnology, the transformative role of data and technology in drug development and manufacturing. Áine delves into the advancements in data accessibility and automation, such as single-cell manipulation and high …

Former biotech investor, Brad Loncar has pivoted his career from investing to reporting on the industry. Instead of serving the biotech bubble, he hopes to reach a wide audience with interest in science. Loncar explains why he switched careers and sets out his ambitions for his channel, Biotech TV.Av RBC Capital Markets

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With a presidential election just round the corner in the US and a new UK budget on the way, financial support for life sciences is high on …

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with CEO of Oxeia, Dr Michael Wyand, where we talk about Oxeia’s work; the unmet critical need for concussion drug t…

Welcome to another episode of Life Sciences 360! Today, we're diving into the intricate world of life sciences leadership with a special guest who's worn nearly every hat in the industry—Taggart McGurrin. Starting in finance, transitioning to law, and tackling leadership roles across strategy, operations, and regulatory affairs, Taggart McGurrin br…

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。今回取り上げた記事はこちら「Déjà Vu In England: Lilly’s Alzheimer’s Drug Kisunla Gets MHRA Yes, But NICE Says No（邦訳：アルツハイマー治療薬ケサンラ承認で議論再び、薬価負担に悩む英国）」URL:　 https://insights.citeline.com/pink-sheet/geography/europe/united-kingdom/deja-vu-in-england-lillys-alzheim…

Discover how Turbine Simulated Cell Technologies is transforming drug development by addressing biases in training data. Guests Bence Szalai, MD, PhD, and Istvan Taisz, MD, PhD, share insights on the challenges of biased AI models in biology and introduce their groundbreaking framework, EFFECT (Evaluation Framework for Predicting Efficacy of Cancer…

We love to hear from our listeners. Send us a message. It might just be coincidence, but it sure seems like Bill Enright has a knack for making big moves at inopportune times, then turning the expected outcome on its ear. For example, he signed on as CEO at Altimmune when the company was struggling mightily. Enright had a turnaround plan in hand, b…

Send us a text In this episode of the Decoding Health podcast, Jeremy Koenig shares his inspiring life journey and educational background, detailing the path that led him to his current work. Jeremy discusses the evolution of his career, emphasizing the importance of understanding and caring about our DNA and genetics. He explains how DNA and genet…

Audio roundup of selected biopharma industry content from Scrip over the business week ended 25 October 2024. In this episode: Merck & Co’s Modifi acquisition; scenarios for new obesity drugs; Astellas gets US approval for claudin drug Vyloy; iTeos builds TIGIT lead; and execs discuss AI in clinical trials.https://insights.citeline.com/scrip/quick-…

EY recently published their 18th annual Pulse of the MedTech Industry report, highlighting how—despite steadily rising profits year-over-year—devicemakers large and small are still being squeezed by the cost of doing business and waning investor enthusiasm. During AdvaMed’s MedTech Conference this month in Toronto, John Babbitt, partner on the life…

Katie Binns, director of product management for Morningstar Indexes, discusses bank loans’ benefits even as interest rates are expected to fall. William Kerwin, equity analyst for Morningstar Research Services who covers Apple, reveals the two main things he wants to hear about on the earnings call. What Are Bank Loans? Bank Loans vs. Junk Bonds Th…

In this episode, Francesca Augustine, founder of Neftwork, discusses the intersection of art and blockchain technology, exploring how her platform leverages blockchain to ensure continuous royalties for artists and increase transparency in the art world. She shares insights into how tokenization can revolutionize the art market, providing security,…

Join us as Dr. Aravind Asokan from Duke University explores cutting-edge technologies revolutionizing advanced therapies, including CRISPR, mRNA, viral vectors, and cell therapies. He shares key lessons from past challenges, discusses scalability, product quality, and how integrating various therapeutic approaches is shaping the future of disease t…

Send us a text In this episode of the Decoding Health podcast, we explore the world of cellular therapies, starting with a basic explanation of what these specialized cells are and why they play a significant role in medical research. We dive into the potential uses of embryonic cells, touching on their applications and the legal and ethical concer…

As the biopharma industry strives to ensure that clinical trials reflect the rich diversity of the patient populations they aim to serve, the challenges to make this possible have fallen on the trial sites. In a recent webinar, Syneos Health experts Jane Bentley and Juliette Roberts from our Oncology Therapeutic Strategy & Innovation team, and Kell…

Christine Benz, Morningstar’s director of personal finance and retirement planning, interviews financial experts about different aspects of retirement in ‘How to Retire,’ the companion podcast to her book of the same name. In this episode, Christine talks with financial planning expert Jeff Levine about the importance of tax planning in retirement.…

In this episode, Dr. Andree Bates speaks with Dr. Jordan Lane, Chief Scientific Officer of Ignota Labs, about how explainable AI is transforming the pharmaceutical industry. They explore how Ignota Labs leverages AI to rescue drug projects that previously failed due to safety concerns. Dr. Lane highlights the groundbreaking technology behind the Sa…

In this episode of Life Sciences 360, host Harsh Thakkar sits down with Marc Sheetz, Associate Dean of Research at Midwestern University's College of Pharmacy, to discuss the growing concern of antimicrobial resistance and the field of pharmacometrics. Marc sheds light on how pharmacometrics is shaping the future of medicine by using predictive mod…

Chris Ellis, CEO and Adam Stevenson, president, both cofounders of Thatch, join Julie Yoo and Jay Rughani of a16z Bio + Health. In early 2020, a new policy called ICHRA altered the insurance market, which had remained largely unchanged for decades. As you’ll hear in the episode, it’s been slow to catch on — but the cofounders of Thatch think it’s a…

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we are halfway through Breast Cancer Awareness Month, our news highlights this week focus on studies that could advance the treatment of …

Emma and Summer meet with oncology analysts Neha Anand, Anna Simmons, and Nkiru Ibeanu, to share insights from the European Society of Medical Oncology (ESMO) conference.Av Citeline

In this episode, Dr. Na-Ri Oh and Ian Wendt sit down with Philip Vyt, a renowned expert in omnichannel strategy and founder of Shyft, a consultancy specializing in omnichannel approaches for biopharma. They delve into the key concepts behind omnichannel and its distinction from multichannel, emphasizing the centrality of healthcare professionals (H…

We love to hear from our listeners. Send us a message. While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (CB1) inverse agonist monlunabant last month, Skye Bioscience Chairman and CEO Punit Dhillon is shaking it off. He's confident that his company's antibo…

Send us a text In this episode of the Decoding Health Podcast, Dr. Neil Morris shares his journey into the field of medicine and what motivated him to pursue it. The discussion covers cholesterol testing, advancements in technology, and how Dr. Morris’s education shaped his career. Dr. Morris provides an in-depth look at stem cell therapy, focusing…

Audio roundup of selected biopharma industry content from Scrip over the business week ended 18 October 2024. In this episode: J&J looks to Tremfya as Stelara declines; Pfizer’s Hympavzi may find hemophilia B niche; big pharma’s cell and gene therapy realities; M&A took a holiday in Q3; and last rites for Sanofi’s RIPK1 drug.https://insights.citeli…

Pink Sheet reporter and editors discuss an emerging pharma strategy to avoid Medicare price negotiations (:25), legal wrangling related to compounding GLP-1 drugs for obesity and diabetes (14:20), and the varying opinions of FDA officials on the acceptability of artificial intelligence models that are not fully explainable (29:08)#pharma #businessM…

At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future. Fierce Biotech’s Gabrielle Masson sat down with Liang Schwei…

Dan Lefkovitz, Morningstar Indexes strategist, discusses why it’s important to be ready for a range of outcomes during a market rotation. Nic Owens, equity analyst for Morningstar Research Services, talks about his outlook for Boeing stock ahead of earnings. Trends from the Q3 Market Rotation Extending into Q4 Key Moments Sparked Market Volatility …

In the newest BioWorld Insider podcast, Victoria Lipinska, the America's lead for Quantum Innovation Centers at IBM Quantum, talks about the future of drug development using quantum computing. “The new technology is a completely different branch of computing as opposed to what we know right now, and it's meant to complement what we know, not to rea…

In this episode, Sandeep Banga, the founder of Scribble, discusses how his AI-powered clinician assistant is designed to reduce the workload for home health nurses by automating documentation processes. He also shares insights on the challenges of balancing innovation with data security and compliance in the healthcare industry, while highlighting …

빅파마들은 세포유전자 치료제를 출시하면서 이러한 치료의 비용과 복잡성이라는 현실적인 문제에 직면해 있습니다. 최근 개최된 메사 세포유전자 회의를 취재한 Scrip 기사를 요약한 내용입니다. https://scrip.citeline.com/SC151041/Big-Pharma-Faces-Cell-And-Gene-Therapy-Market-RealitiesPlaylist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-miniAv Citeline

Christine Benz, Morningstar’s director of personal finance and retirement planning, interviews financial experts about different aspects of retirement in ‘How to Retire,’ the companion podcast to her book of the same name. In this episode, Christine sits down with Washington Post personal finance columnist and author Michelle Singletary. They talk …

In this episode of "AI for Pharma Growth" Dr Andree Bates sits down with Ken Pomella, CEO of RevStar, to delve into the intricate balance between innovation and ethical responsibility in the development of AI technologies. They explore the ethical challenges that AI poses, particularly in the pharmaceutical and healthcare sectors, and discuss ways …

Imagine knowing how your body will respond to a medication before you even take it! In this episode, Harsh Thakkar interviews Sarah Rogers, co-founder and president of the American Society of Pharmacovigilance (ASP) and an Assistant Professor at Texas A&M. Together, they dive deep into the fascinating world of pharmacogenomics—how your genetic make…

The latest episode of the DDW Highlights podcast is now available to listen to. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Recently, the Society for Neuroscience's annual meeting took place, so the headlines have been dominated by the latest discoveries related to the …

Jonathan Lim is the CEO of Erasca, but his career path took him on a fascinating journey from practicing as a surgeon to leading life science companies. In a recent conversation, Lim shared valuable insights about his transition to the biotech world, his leadership experiences, and the lessons he's learned while founding and guiding organizations t…

Audio roundup of selected biopharma industry content from Scrip over the business week ended 11 October 2024. In this episode: making cell and gene therapies more accessible; Roche’s obesity plans; Biosecure and Indian firms; IPOs begin to recover; and Nxera looks to the future.https://scrip.citeline.com/SC151048/Quick-Listen-Scrips-Five-MustKnow-T…

In this episode, we dive into the world of gene therapy logistics with Cryoport Systems' innovative Elite Ultra Cold shipping system. Mike Dybicz and Khoa Tran are in the hotseat to discuss how their solution addresses critical challenges in transporting temperature-sensitive gene therapies. The pair explain how Cryoport Elite offers extended hold …

We love to hear from our listeners. Send us a message. Allan Shaw is back with us this week to dig into the complexities of strategic hiring in biotech. We cover strategies for the step-wise assembly of effective executive teams, the importance of aligning key hires with clinical and regulatory milestones, managing salaries in line with cash runway…

In this episode of The Factor, Ryan Doxey (Senior Director of Technical Services at Kymanox) and David Harrell (CEO of Helixomer) discuss the innovative potential of RNA Origami in transforming drug development and precision medicine, and the challenges faced by startups in this complex landscape. So what exactly is RNA Origami? About the Factor: T…

Send us a text In this episode of the Decoding Health podcast, S. Thaddeus Connelly, an expert Oral and Maxillofacial Surgeon (OMFS), shares insights from his extensive educational background and professional experience. Thaddeus discusses his specialization in diagnosing and treating joint issues, highlighting the signs and solutions for common pr…